CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients
Su Yeong Kim, Na Mi Lee, Sin Weon Yun, Soo Ahn Chae, In Seok Lim, Eung Sang Choi, Dae Yong Yi
Clin Exp Pediatr. 2019;62(10):400-404.   Published online July 3, 2019
DOI: https://doi.org/10.3345/kjp.2019.00115

Excel Download

Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients
Korean Journal of Pediatrics. 2019;62(10):400-404   Crossref logo
Link1 Link2 Link3

Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal Calprotectin
Journal of Clinical Medicine. 2021;10(17):3905   Crossref logo
Link1

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention
Alimentary Pharmacology & Therapeutics. 2011;34(2):243-251   Crossref logo
Link1 Link2

Review article: esomeprazole − the first proton pump inhibitor to be developed as an isomer
Alimentary Pharmacology & Therapeutics. 2003;17:1-4   Crossref logo
Link1 Link2

M1709 Proton Pump Inhibitor Based Triple Therapy Combined with Bismuth Is Superior to Proton Pump Inhibitor Based Triple Therapy Only for Helicobacter pylori Eradication. (Preliminary Data)
Gastroenterology. 2008;134(4):A-402   Crossref logo
Link1 Link2

EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS
Inflammatory Bowel Diseases. 2021;27(Supplement_1):S6-S6   Crossref logo
Link1 Link2

EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS
Gastroenterology. 2021;160(3):S8-S9   Crossref logo
Link1 Link2

Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia
Gastroenterology. 2017;152(5):S860   Crossref logo
Link1 Link2

P275 New non-invasive biomarkers of intestinal inflammation in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin – pilot study
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i311-i312   Crossref logo
Link1 Link2

Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort
Clinica Chimica Acta. 2013;416:41-47   Crossref logo
Link1 Link2